Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,130 | $2,066 | $951 | $1,092 |
| - Cash | $265 | $55 | $33 | $201 |
| + Debt | $52 | $52 | $3 | $3 |
| Enterprise Value | $3,918 | $2,063 | $922 | $894 |
| Revenue | $1 | $4 | $5 | $1 |
| % Growth | -74.1% | -15.3% | 339.4% | – |
| Gross Profit | -$2 | $4 | $5 | $1 |
| % Margin | -168% | 100% | 100% | 100% |
| EBITDA | -$336 | -$222 | -$167 | -$107 |
| % Margin | -32,345.4% | -5,519.8% | -3,523.3% | -9,905.4% |
| Net Income | -$298 | -$215 | -$164 | -$108 |
| % Margin | -28,720.7% | -5,345.9% | -3,460.4% | -9,985.3% |
| EPS Diluted | -3.69 | -3.69 | -3.15 | -2.8 |
| % Growth | 0% | -17.1% | -12.5% | – |
| Operating Cash Flow | -$226 | -$166 | -$115 | -$89 |
| Capital Expenditures | -$4 | -$5 | -$2 | -$0 |
| Free Cash Flow | -$230 | -$171 | -$117 | -$89 |